Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This is a multicenter, randomized, controlled, open-label Phase III clinical trial, aimed at evaluating the efficacy and safety of BEBT-908 combined with rituximab (R) compared to investigator-selected standard chemotherapy regimens \[Standard of Care (SOC)\] \[i.e., rituximab-gemcitabine-oxaliplatin (R-GemOx) or rituximab-ifosfamide-carboplatin-etoposide (R-ICE)\] for the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).

Trial Details

NCT ID
NCT06792253
Phase
PHASE3
Sponsor
BeBetter Med Inc
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Ifupinostat Hydrochloride for Injection
  • Rituximab Injection
  • Gemcitabine Hydrochloride for Injection
  • Oxaliplatin Injection
  • Etoposide Injection
  • Ifosfamide for Injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • The subject has been fully informed and is willing to sign the Informed Consent Form (ICF).
  • Age is ≥18 years and ≤75 years, both men and women are eligible.
  • Pathologically diagnosed as diffuse large B-cell lymphoma according to the 2022 World Health Organization classification, confirmed by central path…
  • Measurable lesions \[The criteria for measurable lesions are: the longest diameter of lymph node lesions measured by enhanced Computed Tomography (…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →